Avatrombopag
from OncoPharm Hosted by John Bossaer
Avatrombopag's FDA-approval prompts discussion of both the indication and drug itself. Finally, the publication of the SELECT-D study allows us to dig deeper into the data of a DOAC vs. LMWH in cancer-associated VTE.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 17 minutes long.
When was this OncoPharm episode published?
This episode was published on May 25, 2018.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.